Literature DB >> 1325358

Antinociception after intracerebroventricular administration of naltrindole in the mouse.

A Stapelfeld1, D L Hammond, M F Rafferty.   

Abstract

Intracerebroventricular (i.c.v.) injection of the delta-opioid receptor antagonist naltrindole hydrochloride (2.2-22.2 nmol) in mice produced a dose-dependent increase in tail flick and hot plate latencies with respective ED50 and 95% confidence limits of 10.6 (8.3-13.9) and 16.4 (9.2-62.3) nmol. This increase in response latencies was antagonized by 1 mg/kg s.c. naloxone or by i.c.v. coadministration of 1.4 nmol ICI-174,864, a selective peptidergic delta-receptor antagonist. Pretreatment 24 h earlier with the irreversible mu-receptor antagonist beta-funaltrexamine (6 nmol i.c.v.) or 1 h earlier with the selective kappa-receptor antagonist nor-binaltorphimine (100 nmol i.c.v.) did not attenuate the antinociceptive effects of naltrindole. These data indicate that high doses of naltrindole may have agonist activity at supraspinal delta-opioid receptors in the mouse.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325358     DOI: 10.1016/0014-2999(92)90129-r

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Sensitivity to μ-opioid receptor-mediated anti-nociception is determined by cross-regulation between μ- and δ-opioid receptors at supraspinal level.

Authors:  J J Ballesta; J Cremades; M Rodríguez-Muñoz; J Garzón; C C Faura
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine.

Authors:  Toni S Shippenberg; Vladimir I Chefer; Alexis C Thompson
Journal:  Biol Psychiatry       Date:  2008-10-31       Impact factor: 13.382

Review 3.  Targeting endogenous mu- and delta-opioid receptor systems for the treatment of drug addiction.

Authors:  T S Shippenberg; A LeFevour; V I Chefer
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.